Oncolix, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.oncolixbio.com
Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer
Phase 1
- Conditions
- Peritoneal CancerOvarian CancerFallopian Tube Cancer
- Interventions
- Biological: Prolanta, a human prolactin receptor antagonist
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- Oncolix, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02534922
- Locations
- 🇺🇸
ITOR/GHS, Greenville, South Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath